FDA Approves Smallpox Vax For Use Against Mpox

Reuters reports:

The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions’ smallpox vaccine for use in people at high risk of mpox infection, sending the drugmaker’s shares 5% higher on Friday.

The FDA clearance, announced late on Thursday by the company, makes the vaccine – called ACAM2000 – the second approved shot against mpox in the U.S. after Bavarian Nordic’s Jynneos.

The Emergent vaccine, however, cannot be administered to those with weakened immune systems, including people with HIV.

Read the full article.

Today Emergent announced that the FDA has approved the supplemental Biologics License Application for the expansion of the indication for its smallpox vaccine to include immunization for the prevention of mpox disease in high-risk individuals. Learn more: https://t.co/yjUunwoQZN pic.twitter.com/IcuLDWLGgw

— Emergent (@EmergentWeGo) August 30, 2024